Abstract The purpose of the study was to evaluate serum concentrations of selected growth factors and the diffusing capacity of the lung for carbon monoxide (DLCO) in 21 females treated for systemic lupus erythematosus. The control group consisted of 24 healthy women. Based on the high-resolution computed tomography (HRCT), patients were allocated to a subgroup of 11 subjects (HRCT-negative) and a subgroup of 10 with pulmonary abnormalities (HRCT-positive). In HRCT-negative patients a significantly higher level of TNF-a as compared with the control was observed and positive correlation between TNF-a and bFGF was revealed in this subgroup and in the total group of patients. DLCO was below the predicted value in 13 patients. No correlations between DLCO and growth factors concentrations were observed. DLCO reduction in asymptomatic, with respect to the respiratory system, SLE patients suggests a need for long-term monitoring of this parameter. The role of TNF-a in these patients requires further investigations.
Introduction
Systemic lupus erythematosus (SLE) is organ non-specific autoimmune disease where the damage of organ structure and function is associated with the action of different autoantibodies and deposition of immune complexes in tissues. The respiratory system can also become involved; the disease most frequently develops within the pleura, causes pulmonary interstitial changes, and damages of pulmonary vessels. Diaphragm dysfunction can occur and compromise the function of the respiratory system [1] [2] [3] . An ongoing autoimmune inflammatory process causes the activated immunocompetent cells to release factors that initiate and support the inflammatory response. This may result in organ fibrosis including pulmonary lesions [4] . Angiogenesis, influenced by various stimulating and inhibiting growth factors, e.g., vascular-endothelial growth factor (VEGF) and its soluble receptors (sVEGF R1, sVEGF R2), and its disturbances, may also play a role in the above-mentioned process [5, 6] .
The purpose of the study was to assess serum concentrations of selected growth factors, and evaluate the diffusing capacity of the lung for carbon monoxide (DLCO) in SLE patients.
Patients and controls
The investigations were carried out in 21 consecutive women with SLE (mean age 51 ± 12.4 years), with no symptoms of respiratory tract disease. All patients had already been treated from several months to several years. In the examined persons any pulmonary toxic medications have not been applied prior to the current therapy. The patients with occupational exposures for crystalline silica, solvents and pesticides were excluded. Pharmacotherapy included the following drugs applied as a single or in various combinations: prednisone (5-10 mg daily), azathiopirine (50-100 mg daily), cyclophosphamide (periodic administration 200 mg daily), cyclosporine A (50-100 mg daily) and prolactin-suppressive drug-dopamine agonistquinagolide (25-50 lg daily) [7] . Diagnosis was based on the criteria developed by the American Rheumatism Association (ARA) in 1982 [8] , and then revised in 1997 [9] . The patients had 4 of 11 criteria for SLE; most with mild-to-moderate disease had SLE disease activity index (SLEDAI) of\10 score or slightly higher on qualification to study. Three or four organs were affected. Three subjects were cigarette smokers, the remaining 18 did not smoke. SLE seroactivity and screening tests for autoimmune disease were performed, including erythrocyte sedimentation rate, anti-DNA antibodies, anti-nuclear antibodies, anticardiolipin antibodies, and serum complement factor C3. Based on the high-resolution computed tomography (HRCT) scans, patients were allocated to a subgroup of 11 patients with no lung or pleural lesions (HRCT-negative), and a subgroup of 10 with reticulonodular opacities mainly in the lower portion of the lungs, parenchymal enhancement or honeycomb pattern (HRCT-positive). The control group consisted of age and place of residence-matched 24 healthy women (mean age 51 ± 15.3 years) without pharmacotherapy whose blood tests were within normal range.
Methods
Laboratory measurements included serum levels of the following growth factors and soluble receptors: VEGF, sVEGF R1, sVEGF R2, basic fibroblast-growth factor (bFGF), hepatocyte growth factor (HGF), transforming growth factor-b1 (TGFb1) and tumor necrosis factor-a (TNF-a). ELISA assays were performed using RayBioÒ or Diaclone kits on the lQuant TM Microplate Spectrophotometer. Blood samples were collected between 7 and 8 a.m. from patients after an overnight fast, randomly coded, and stored at a temperature of below -70°C. Subsequent investigations were performed as an open randomized blind trial.
Pulmonary function was assessed using the single-breath DLCO with normal value C80% of the predicted value [4] .
DLCO percentage was expressed with the correction for hemoglobin concentration and after simultaneously measured alveolar volume (VA) to calculate DLCO/VA index. Pulmonary function tests were performed by Masterlab spirometer (Masterlab E. Jaeger, Würzburg, Germany). Vital capacity (VC) was also checked using 80% of predicted value as the lower limit of normal.
The following investigation scheme was adopted: (1) comparison of serum concentrations of selected cytokines between the patient group (21 female patients with SLE) and the control (24 healthy women), (2) comparison of serum concentrations of selected cytokines between HRCT-negative SLE subgroup (n = 11) and the control, (3) comparison of serum concentrations of selected cytokines between HRCT-positive SLE subgroup (n = 10) and the control, (4) analysis of relationships between particular serum cytokine concentrations, (5) analysis of relationships between DLCO and cytokine concentrations and (6) comparison of DLCO frequency below 80% predicted value between HRCT-positive-and HRCT-negative subgroups.
Statistical analysis
The results were subject to normal distribution analysis by the Shapiro-Wilk's test. Arithmetic means (X) and standard deviations (SD) were calculated. A test for equality of variances was carried out prior to a comparison of group/ subgroup means. Snedecor's F test for the difference of two variances was used. When variable distribution was normal and equality of variances was confirmed, further calculations were made using parametric Student's t test of unrelated variables. When the condition of normal distribution did not apply, further analyses were carried out with a non-parametric test. Relationships between parameters investigated were tested by Pearson's analysis; correlation coefficients were calculated to determine relationships between cytokine concentrations, and between DLCO and cytokine concentrations. Fisher's exact test was applied to determine the DLCO frequency defined as the percentage of individuals with value\80% of predicted one in relation to the results of HRCT. Difference between mean values was considered statistically significant at P \ 0.05, and highly significant at P \ 0.001.
Results
Mean serum VEGF, bFGF, HGF, and TNF-a concentrations of SLE patients (3,494.90 ± 1,879.35 pg/mL, 1,432.18 ± 3,030.80 pg/mL, 1,478.14 ± 1,258.92 pg/mL, and 19.24 ± 22.33 pg/mL, respectively) were higher than in the control (2,869.42 ± 1,625.70 pg/mL, 869.28 ± 1,737.60 pg/mL, 1,205.89 ± 531.70 pg/mL, and 13.38 ± 11.85 pg/mL, respectively) while sVEGF R1, sVEGF R2 and TGFb1 (0.15 ± 0.08 ng/mL, 9,046.79 ± 4,070.94 pg/ mL, 11.08 ± 5.01 ng/mL, respectively) were lower as compared to the control subjects (0.24 ± 0.23 ng/mL, 9,541.52 ± 5,350.57 pg/mL, 12.73 ± 4.38 ng/mL, respectively). However, the differences between mean values of the parameters did not reach the level of statistical significance. Only TNF-a differences got near statistical significance. The HRCT-negative subgroup of SLE patients had a significantly higher level of TNF-a than the control. No statistically significant differences were revealed as to the concentrations of other cytokines investigated ( Table 1) . HRCT-positive subjects had the lowest TNF-a levels among the examined groups/subgroups. However, no statistically significant differences were found between HRCT-positive patients and the control when serum concentrations of growth factors and soluble receptors were compared (Table 1 ).
In the whole patient group and HRCT-negative subjects, a statistically significant positive correlation between TNF-a and bFGF was revealed ( Table 2) . No similar correlations were seen in HRCT-positive patients (Table 2) .
Abnormal DLCO was found in 13 of 21 SLE subjects; seven patients belonged to HRCT-positive, and six patients to HRCT-negative subgroup. The respective mean values in the whole patient group, HRCT-negative-and HRCTpositive subjects were 78.02 ± 19.05, 80.27 ± 17.47, and 75.55 ± 21.31%. No significant difference in frequency of DLCO below 80% was observed between HRCT-positiveand HRCT-negative subgroups of patients (P = 0.659). No statistically significant differences were found in the whole patient group and in HRCT subgroups as to correlations between DCLO, cytokines and soluble receptors concentrations (Table 3) .
Mean VC of the whole patient group was 100.58%; in HRCT-positive-and HRCT-negative subgroups the values were 99.76 and 103.14%, respectively. Values below \80% were only seen in two patients.
Discussion
There are only few studies investigating pulmonary function of asymptomatic with respect to respiratory system, patients treated for SLE [3, 10, 11] . As it was mentioned before, the respiratory system is the area where autoantibodies and/or immune complexes may cause damage. Consequently, fibrosis may be initiated both as a result of autoimmune inflammatory processes and processes causing damage to the pulmonary vasculature. In angiogenesis, vascular endothelium with activating and inhibiting factors play the crucial role [12] . Therefore, we decided to evaluate serum concentrations of selected growth factors, which are the key regulators of angiogenesis. Our results did not show any significant differences in serum VEGF, sVEGF R1, sVEGF R2, TGFb1, HGF, and bFGF concentrations between the study subjects and the controls. Only TNF-a levels proved significantly higher in HRCT-negative patients with SLE. The function of TNF is inhibited by its soluble receptors (sTNFR) [13, 14] ; thus, lower concentrations thereof should enhance TNF activity. Our previous results had not revealed essential changes in sTNFRs concentrations in the course of therapy for SLE [7] . Therefore, we suppose that higher serum levels of TNF-a observed in the present study may be the effect of higher production of this factor in SLE. The lowest TNF-a was observed in HRCT-positive patients and it remains unaccounted for. It may be that, following the development of lesions, the levels and activity of TNF-a normalize. The significant positive correlation between serum TNF-a and bFGF levels seen in the whole patient group and HRCTnegative subjects and the lack of similar correlation in HRCT-positive patients might support such hypothesis in the light of the role of bFGF in fibrosis [15] . The results concerning the level of TNF-a in our study differ from the earlier ones obtained by other authors who observed increased serum level of this factor in SLE patients [16, 17] , especially in SLE subjects with pulmonary involvement [17] . The demonstrated differences could be partially explained by lower disease activity in our patients (calculated on the day of blood sampling SLEDAI score was\10 or slightly higher) [18] . It should be stressed now, that the group of our patients consisted of SLE-treated subjects and it is known that the applied therapy can modify the serum levels of the analyzed growth factors.
Basic FGF is one of the FGF families and is mitogenic for a variety of cells including fibroblasts and is also a known chemotactic and as it was mentioned angiogenic factor [19] [20] [21] . We did not observe statistically significant differences between its serum levels in the whole patient group and subgroups when compared with the control, which remains in accordance with the results of earlier reports [20, 22] . It is worth mentioning, however, that the mean level of this factor was higher in SLE patients than in the controls.
It is believed that a decrease in DLCO is the best indicator of compromised pulmonary function (1) . DLCO reduction is observed in diseases with alveolar gas exchange surface reduction and damage to pulmonary capillaries [23] . Our results concerning DLCO are in accordance with the earlier studies, where reduced values of the parameter were demonstrated in SLE patients both with and without fibrotic lesions on HRCT scans [1] . It should also be noticed that no statistically significant correlations were seen between DLCO and serum growth factors concentrations in our patients with SLE. The reduction of DLCO in free of the respiratory symptoms SLE patients suggests a need for long-term monitoring of the parameter, starting at diagnosis and further on not only in periodic aspect of the disease activity assessment but also in periodic assessment of the respiratory system function.
We conclude that in treated patients with mild-to-moderate SLE, the reduced diffusing capacity of the lung for carbon monoxide is not associated with serum concentrations of examined angiogenic factors and with pulmonary abnormalities determined by high-resolution-computed tomography. The role of TNF-a in asymptomatic, as far as respiratory system is concerned, SLE patients requires further research. The investigations would have to be aimed at repeat evaluation of the lung lesion development in the above-mentioned patients group, and should be scheduled as a long-term study.
